METHODS: A 62-year-old man was referred to our hospital in February 2023 because of dizziness and numbness of the right lower extremity without headache or fever for more than four weeks. The patient was diagnosed with limited-stage SCLC. He received 8 cycles of chemotherapy combined with maintenance bevacizumab therapy and achieved a PFS of over 7 mo.
CONCLUSIONS: The combination of bevacizumab and irinotecan effectively alleviated brain metastasis in SCLC and prolonged PFS.
方法:2023年2月,一名62岁的男子因右下肢头晕麻木而被转诊至我院,治疗时间超过4周,无头痛或发热。患者被诊断为局限期SCLC。他接受了8个周期的化疗联合贝伐单抗维持治疗,PFS超过7个月。
结论:贝伐单抗联合伊立替康可有效缓解SCLC脑转移,延长PFS。